Hospital
Hampshire Memorial Hospital, INC.
Hampshire Memorial Hospital, INC. was paid $9.58M by Medicaid between Jan 2018 and Dec 2024, across 120 billing codes. Its largest line is 99283, emergency room visit (moderate) — 22% of everything it billed.
33Billing provider infoHAMPSHIRE MEMORIAL HOSPITAL, INC.
ROMNEY, WV 26757
ROMNEY, WV 26757
33aNPI1396897203assigned 01/18/2007
33bProvider typeCritical Access Hospital
28Total paid$9.58M
24GClaims124,539
24DCodes billed120
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in West Virginia
Rank by total paid#6 of 24
Median peer was paid$3.57M
This provider vs. median2.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official CHAMBERS, JILL controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 26,062 | $2.28M | |
| 2019 | 14,893 | $1.23M | |
| 2020 | 24,940 | $2.00M | |
| 2021 | 25,672 | $1.73M | |
| 2022 | 11,417 | $698K | |
| 2023 | 12,322 | $889K | |
| 2024incomplete | 9,233 | $762K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 22% | 12,911 | 11,302 | $2.15M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 19% | 5,763 | 3,887 | $1.81M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 4,417 | 3,496 | $1.03M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 428 | 403 | $361K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 3.7% | 11,783 | 9,912 | $356K |
| 80053 | Comprehensive metabolic panel | 3.4% | 9,237 | 8,170 | $328K |
| 36415 | Collection of venous blood by venipuncture | 1.9% | 12,323 | 10,253 | $185K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.9% | 636 | 602 | $178K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.8% | 1,988 | 1,651 | $177K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 1,872 | 1,722 | $175K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.7% | 1,231 | 1,142 | $163K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.7% | 4,264 | 3,669 | $162K |
108 more codes
| 84443 | Thyroid stimulating hormone (TSH) | 1.5% | 3,325 | $142K |
| 71046 | Radiologic examination, chest; 2 views | 1.4% | 2,604 | $130K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 1,630 | $126K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.3% | 1,044 | $120K |
| 81001 | 1.2% | 3,729 | $119K | |
| 80061 | Lipid panel | 1.2% | 2,556 | $116K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 2,087 | $108K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.0% | 2,911 | $100K |
| 84484 | <1% | 2,548 | $73K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,392 | $70K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 120 | $69K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 1,970 | $65K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,021 | $65K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,006 | $64K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,185 | $56K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,359 | $53K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,693 | $52K |
| 71045 | Radiologic examination, chest; single view | <1% | 1,522 | $48K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 222 | $47K |
| 87081 | <1% | 1,173 | $43K | |
| 83690 | <1% | 997 | $41K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 683 | $41K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,165 | $39K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 682 | $36K |
| 82948 | <1% | 1,402 | $34K | |
| 87186 | <1% | 916 | $32K | |
| 83880 | <1% | 626 | $29K | |
| 80306 | <1% | 524 | $28K | |
| 85610 | <1% | 1,470 | $28K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 446 | $26K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 59 | $23K |
| 81025 | <1% | 440 | $21K | |
| 84439 | <1% | 600 | $21K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 380 | $20K |
| 85379 | <1% | 323 | $20K | |
| 94664 | <1% | 402 | $19K | |
| 82607 | <1% | 392 | $19K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 165 | $18K |
| 96376 | <1% | 168 | $16K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 214 | $16K |
| 87070 | <1% | 182 | $16K | |
| 81003 | <1% | 754 | $16K | |
| 80076 | <1% | 341 | $15K | |
| 87077 | <1% | 361 | $15K | |
| 87040 | <1% | 202 | $15K | |
| 83735 | <1% | 662 | $12K | |
| 73564 | <1% | 198 | $12K | |
| 83605 | <1% | 305 | $11K | |
| 82746 | <1% | 228 | $11K | |
| 87634 | <1% | 355 | $10K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 561 | $10K |
| 84703 | <1% | 142 | $10K | |
| 73630 | <1% | 158 | $8K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 127 | $7K |
| 84466 | <1% | 167 | $7K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 86 | $7K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 27 | $6K |
| 72110 | <1% | 63 | $6K | |
| 87205 | <1% | 125 | $6K | |
| 94760 | <1% | 111 | $6K | |
| 82550 | <1% | 177 | $5K | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 163 | $5K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 207 | $5K |
| 73030 | <1% | 116 | $5K | |
| 97161 | <1% | 57 | $5K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 52 | $5K |
| G0378 | Hospital observation service, per hour | <1% | 28 | $5K |
| 73610 | <1% | 104 | $5K | |
| 83540 | <1% | 172 | $4K | |
| 87420 | <1% | 82 | $4K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 110 | $4K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 65 | $3K |
| 76536 | <1% | 26 | $3K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 31 | $3K |
| 73130 | <1% | 72 | $3K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 146 | $3K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 15 | $3K |
| 82570 | <1% | 106 | $3K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 62 | $2K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 108 | $2K |
| 86140 | <1% | 235 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 25 | $2K |
| 12001 | <1% | 17 | $2K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 27 | $2K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 27 | $2K |
| 85651 | <1% | 50 | $2K | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 346 | $2K |
| 82728 | <1% | 40 | $1K | |
| 73110 | <1% | 32 | $1K | |
| 82043 | <1% | 54 | $1K | |
| 97597 | <1% | 14 | $1K | |
| 82803 | <1% | 34 | $1K | |
| 73502 | <1% | 24 | $1K | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 15 | $902.00 |
| 72040 | <1% | 13 | $636.64 | |
| 72100 | <1% | 13 | $594.03 | |
| 82565 | <1% | 28 | $586.62 | |
| 85652 | <1% | 66 | $579.93 | |
| 87428 | <1% | 12 | $430.19 | |
| 82947 | <1% | 55 | $382.29 | |
| 36600 | <1% | 17 | $281.73 | |
| 85730 | <1% | 12 | $245.78 | |
| 84145 | <1% | 13 | $63.22 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 43 | $60.68 |
| J3490 | Unclassified drugs | <1% | 31 | $44.86 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 29 | $29.83 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 15 | $3.58 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 194 | $0.01 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCHAMBERS, JILL (MANAGER INSURANCE CREDENTIALING)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.